These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39386278)

  • 1. Large scale analysis of the SARS-CoV-2 main protease reveals marginal presence of nirmatrelvir-resistant SARS-CoV-2 Omicron mutants in Ontario, Canada, December 2021-September 2023.
    Duvvuri V; Shire F; Isabel S; Braukmann T; Clark S; Marchand-Austin A; Eshaghi A; Bandukwala H; Varghese N; Li Y; Sivaraman K; Hussain H; Cronin K; Sullivan A; Li A; Zygmunt A; Ramotar K; Kus J; Hasso M; Corbeil A; Gubbay J; Patel S
    Can Commun Dis Rep; 2024 Oct; 50(10):365-374. PubMed ID: 39386278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
    Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
    J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
    Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
    EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
    Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M
    Dawood AA
    Adv Med Sci; 2023 Mar; 68(1):1-9. PubMed ID: 36368287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes.
    Padhi AK; Tripathi T
    Biochem Biophys Res Commun; 2022 Nov; 629():54-60. PubMed ID: 36113178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Prevalence of Nirmatrelvir-Ritonavir Resistance-Associated Mutations in SARS-CoV-2 Lineages From Botswana.
    Choga WT; Bareng OT; Moraka NO; Maruapula D; Gobe I; Ndlovu NS; Zuze BJL; Motshosi PC; Seru KB; Matsuru T; Boitswarelo M; Matshaba M; Gaolathe T; Mosepele M; Makhema J; Tamura TJM; Li JZ; Shapiro R; Lockman S; Gaseitsiwe S; Moyo S
    Open Forum Infect Dis; 2024 Jul; 11(7):ofae344. PubMed ID: 39015352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive study of SARS-CoV-2 main protease (M
    Costacurta F; Dodaro A; Bante D; Schöppe H; Sprenger B; Moghadasi SA; Fleischmann J; Pavan M; Bassani D; Menin S; Rauch S; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Ho J; Harris RS; Stefan E; Schneider R; Kaserer T; Moro S; von Laer D; Heilmann E
    bioRxiv; 2023 Oct; ():. PubMed ID: 37808638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
    Ullrich S; Ekanayake KB; Otting G; Nitsche C
    Bioorg Med Chem Lett; 2022 Apr; 62():128629. PubMed ID: 35182772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
    Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW
    Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational Insights into SARS-CoV-2 Main Protease Mutations and Nirmatrelvir Efficacy: The Effects of P132H and P132H-A173V.
    Xia YL; Du WW; Li YP; Tao Y; Zhang ZB; Liu SM; Fu YX; Zhang KQ; Liu SQ
    J Chem Inf Model; 2024 Jul; 64(13):5207-5218. PubMed ID: 38913174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
    Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
    Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of SARS-CoV-2 Mutations after Nirmatrelvir Treatment in a Lung Cancer Xenograft Mouse Model.
    Kang BM; Kim D; Kim J; Baek K; Park S; Shin HE; Lee MH; Kim M; Kim S; Lee Y; Kwon HJ
    Biomol Ther (Seoul); 2024 Jul; 32(4):481-491. PubMed ID: 38835145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
    Hung YP; Lee JC; Chiu CW; Lee CC; Tsai PJ; Hsu IL; Ko WC
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
    Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
    Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Low-Frequency, Antiviral Resistance Variants in SARS-CoV-2 Isolates in Ontario, Canada, 2020-2023.
    Sjaarda CP; Lau L; Simpson JT; Fattouh R; Biondi MJ; Maguire F; Campigotto A; Feng Y; Tozer K; Wong H; Sung WWL; Kim S; Marshall CR; Sheth PM; Kozak R
    JAMA Netw Open; 2023 Jul; 6(7):e2324963. PubMed ID: 37477915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach.
    Havranek B; Demissie R; Lee H; Lan S; Zhang H; Sarafianos S; Ayitou AJ; Islam SM
    J Chem Inf Model; 2023 Nov; 63(22):7180-7188. PubMed ID: 37947496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.